SAREPTA THERAPEUTICS INC (SRPT) Stock Price, Forecast & Analysis
NASDAQ:SRPT • US8036071004
SRPT Key Statistics, Chart & Performance
The current stock price of SRPT is 18.59 USD. In the past month the price decreased by -13.01%. In the past year, price decreased by -82.51%.
SRPT Technical Analysis
SRPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRPT. SRPT may be in some trouble as it scores bad on both profitability and health.
SRPT Financial Highlights
Over the last trailing twelve months SRPT reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS decreased by -197.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| Debt/Equity | 0.78 |
SRPT Forecast & Estimates
33 analysts have analysed SRPT and the average price target is 30.93 USD. This implies a price increase of 66.35% is expected in the next year compared to the current price of 18.59.
For the next year, analysts expect an EPS growth of -342.71% and a revenue growth 14.25% for SRPT
SRPT Ownership
SRPT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 396.512B | ||
| AMGN | AMGEN INC | 16.66 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.63 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SRPT
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,372 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Company Info
SAREPTA THERAPEUTICS INC
215 First Street, Suite 415
Cambridge MASSACHUSETTS 02142 US
CEO: Douglas S. Ingram
Employees: 1372
Phone: 16172744000
SAREPTA THERAPEUTICS INC / SRPT FAQ
What does SAREPTA THERAPEUTICS INC do?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,372 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Can you provide the latest stock price for SAREPTA THERAPEUTICS INC?
The current stock price of SRPT is 18.59 USD. The price increased by 1.14% in the last trading session.
Does SRPT stock pay dividends?
SRPT does not pay a dividend.
How is the ChartMill rating for SAREPTA THERAPEUTICS INC?
SRPT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for SAREPTA THERAPEUTICS INC?
The Revenue of SAREPTA THERAPEUTICS INC (SRPT) is expected to grow by 14.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is SAREPTA THERAPEUTICS INC worth?
SAREPTA THERAPEUTICS INC (SRPT) has a market capitalization of 1.95B USD. This makes SRPT a Small Cap stock.
What is the Short Interest ratio of SAREPTA THERAPEUTICS INC (SRPT) stock?
The outstanding short interest for SAREPTA THERAPEUTICS INC (SRPT) is 22.36% of its float.